Phase 1 Clinical Trial Of PV-10 In Recurrent Breast Cancer Complete, Says Provectus Pharmaceuticals

Main Category: Breast Cancer
Also Included In: Cancer / Oncology;  Clinical Trials / Drug Trials
Article Date: 29 Oct 2008 - 7:00 PDT

email to a friend   printer friendly   opinions  

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that it has successfully completed its Phase 1 clinical trial of PV-10 in the treatment of recurrent breast carcinoma.

Craig Dees, CEO of Provectus, noted, "We are very pleased with the results of this Phase 1 clinical trial, a classic ascending dose study. Its goals were to determine the safety of the treatment and the appropriate dosage. We have also wanted to show that PV-10 has multi-indication potential. We succeeded in meeting these goals. We are now in a position for a Phase 2 study in recurrent breast carcinoma with our lead oncology drug product candidate PV-10."

Dees continued, "The main focus of the Company's oncology program is the Phase 2 study of the effectiveness of PV-10 on metastatic melanoma. It is being undertaken at multiple centers in Australia and the US. It has enrolled almost 50% of the patients needed to complete the study, and we will continue to accelerate recruitment by adding several additional sites." Recently, "Melanoma Research" published a paper, "Chemoablation of metastatic melanoma using intralesional Rose Bengal," by Provectus Lead Investigator Professor John F. Thompson and his colleagues, Professor Peter Hersey and Dr. Eric Wachter. The paper details the results of the Phase 1 clinical trial that preceded the current Phase 2 trial.

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. www.pvct.com

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

• Additional
• References
• Citations